The Phase 1 Clinical Trials Program at Seattle Cancer Care Alliance is the Pacific Northwest’s first academic-based program of its kind, serving Fred Hutchinson Cancer Research Center and the University of Washington Cancer Consortium.
The mission of the program is to provide a centralized core of expertise for the conduct of first-in-human trials of investigational cancer therapeutic agents. Because conventional therapy is often ineffective for patients with advanced disease, the Phase 1 program offers innovative new agents for patients who have exhausted other treatment options. Potentially speeding the development of new therapies, these trials require a high level of technical and scientific competencies, like those found at SCCA. The program provides unique opportunities for correlative studies that take advantage of consortium research strengths such as world-class PET imaging, proteomics, biomarkers, and genomics cores.
The Phase 1 program is committed to providing a full range of research services to facilitate the development, implementation, and successful completion of clinical trials.
The majority of trials conducted are industry-sponsored. Typical study start-up time for opening a new trial is approximately 90 days. The regulatory review includes scientific board review and internal review board approval. Our program has experience in conducting outpatient (at SCCA) and inpatient trials (at University of Washington Medical Center).
Examples of new treatments being tested in the Phase 1 Program include immunemodulating therapies, targeted therapies, angiogenesis inhibitors, and cytotoxic agents for hematologic and solid tumor cancers.
Clinical Trials Unit
A brand new, dedicated Clinical Trials Unit (CTU) at SCCA is available for patients participating in Phase 1 trials. The new unit includes a nursing station, space for research coordinators, and four rooms where research subjects receive medications and undergo blood draws and other tests. The Patient Chair
Lounge is an adjacent open monitoring space where patients may receive oral drug and continued observation and sample collection. The Lounge features comfortable chairs, flat-panel television and snacks to create a pleasant environment for the patient. The unit operating hours are currently 8 a.m. to 10 p.m., Monday-Friday. If required by the protocol, overnight stays take place at University of Washington Medical Center. The dedicated PK processing lab and Investigational Drug Services are located in close proximity to the CTU.
Our program consists of highly skilled and dedicated staff, nurses and physicians who have extensive research experience and provide the exacting care and attention required to achieve potential breakthrough therapies.
John A. Thompson, MD, Director, Phase 1 Clinical Trials Program, Clinical Research Division, Member, Fred Hutchinson Cancer Research Center, University of Washington Professor, Medical Oncology Division
Laura Q. Chow, MD, Associate Director, Phase 1 Clinical Trials Program, Clinical Research Division, Member, Fred Hutchinson Cancer Research Center, University of Washington Professor, Medical Oncology Division
Martin A. “Mac” Cheever, MD, Director, Solid Tumor Program, Fred Hutchinson Cancer Research Center, University of Washington Professor, Medical Oncology Division
Bojana I. Askovich, PhD, Phase I Program Administrator
Clinical Research Group
Phase 1 Mid-Levels
Phase 1 Program
825 Eastlake Ave. E.
Seattle, WA 98109-1023
Fax: (206) 288-6681